Real-World Evidence Needs for Treatment Sequence Disease Modelling in Refractory Inflammatory Bowel Disease

被引：0
|
作者：
Kodjamanova, P. [1 ]
Sanon, M. [2 ]
Dimova, M. [3 ]
Wu, E. [2 ]
Atanasov, P. [4 ]
机构：
[1] Amaris Consulting, Real World Evidence, London, England
[2] Janssen Global Serv, Global Market Access, Raritan, NJ USA
[3] Janssen Global Serv, HTA Modelling, Horsham, PA USA
[4] Amaris Consulting, Real World Evidence, Barcelona, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1437
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1263
引用
收藏
页码：i2288 / i2288
页数：1
相关论文
共 50 条
  • [1] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Brian Bressler
    Jennifer Jones
    Tracy S. H. In
    Tommy Lan
    Cristian Iconaru
    John K. Marshall
    Advances in Therapy, 2023, 40 : 4421 - 4439
  • [2] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Bressler, Brian
    Jones, Jennifer
    In, Tracy S. H.
    Lan, Tommy
    Iconaru, Cristian
    Marshall, John K.
    ADVANCES IN THERAPY, 2023, 40 (10) : 4421 - 4439
  • [3] RISANKIZUMAB TREATMENT IN INFLAMMATORY BOWEL DISEASE PATIENT WITH PSORIASIS: REAL-WORLD DATA
    Zinger, Adar
    Choi, David
    Choi, Natalie K.
    Fear, Evan N.
    Fine, Zachary D.
    Cohen, Russell D.
    Rubin, David T.
    GASTROENTEROLOGY, 2024, 166 (05) : S1148 - S1149
  • [4] Real-world biologic treatment and associated cost in patients with inflammatory bowel disease
    Brandes, Alina
    Groth, Antje
    Gottschalk, Fraence
    Wilke, Thomas
    Ratsch, Boris A.
    Orzechowski, Hans-Dieter
    Fuchs, Andreas
    Deiters, Barthold
    Bokemeyer, Bernd
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (07): : 843 - 851
  • [5] Calibrating real-world evidence studies against randomized trials: Treatment effectiveness of infliximab in inflammatory bowel disease
    Kirchgesner, Julien
    Desai, Rishi J.
    Schneeweiss, Maria C.
    Beaugerie, Laurent
    Kim, Seoyoung C.
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 41 - 42
  • [6] Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
    Sahyoun, Laura C.
    Fetene, Jonathan
    Mcmillan, Chandler
    Protiva, Petr
    Al Bawardy, Badr
    Gaidos, Jill K. J.
    Proctor, Deborah
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1654 - 1660
  • [7] Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
    Smith, Philip J.
    Fumery, Mathurin
    Leong, Rupert W.
    Novak, Kerri
    Dignass, Axel
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (09) : 1143 - 1156
  • [8] Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
    Laura C. Sahyoun
    Jonathan Fetene
    Chandler McMillan
    Petr Protiva
    Badr Al Bawardy
    Jill K. J. Gaidos
    Deborah Proctor
    Digestive Diseases and Sciences, 2024, 69 : 1654 - 1660
  • [9] Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease
    Kotze, Paulo G.
    Ma, Christopher
    Almutairdi, Abdulelah
    Al-Darmaki, Ahmed
    Devlin, Shane M.
    Kaplan, GilaadG.
    Seow, Cynthia H.
    Novak, Kerri L.
    Lu, Cathy
    Ferraz, Jose G. P.
    Stewart, Michael J.
    Buresi, Michelle
    Jijon, Humberto
    Mathivanan, Meena
    Heatherington, Joan
    Martin, Marie-Louise
    Panaccione, Remo
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (06) : 626 - 637
  • [10] Association of inflammatory bowel disease with the risk of Parkinson's disease: A meta-analysis of real-world evidence
    Hussain, Salman
    Najmi, Abul Kalam
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 151 - 151
12345